The current standard of cervical-
cancer prevention requires
three clinical visits: one for
screening, one for a colposcopically
guided (i.e., magnified) biopsy
for women with abnormal
screening results, and one for
treatment of precancerous conditions.
Single cytologic screenings
are insensitive and do not
provide sustained reassurance
with regard to the risk of cancer.
Program effectiveness is achieved